GUARDANT HEALTH, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.58 USD | +5.43% |
|
+23.77% | -12.61% |
Presenter SpeechUnknown Executive (Executives)[Presentation]
Plea...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
Calendar
2024-05-15
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
22.37
USD
Average target price
37
USD
Spread / Average Target
+65.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.61% | 2.74B | |
| -26.32% | 9.87B | |
| -12.92% | 2.24B | |
| -18.30% | 1.63B | |
| +60.23% | 1.39B | |
| +25.75% | 772M | |
| -4.59% | 760M | |
| -20.92% | 516M | |
| -0.60% | 310M | |
| +6.47% | 219M |
- Stock Market
- Equities
- GH Stock
- News Guardant Health, Inc.
- Transcript : Guardant Health, Inc. - Analyst/Investor Day